The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest lung cancer drugs market share, and Middle East was the fastest-growing region in 2022.

The global lung cancer drugs market is expected to grow from $32.67 billion in 2022 to $36.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The global lung cancer drugs market size is expected to grow to $54.43 billion in 2027 at a CAGR of 10.5%.

Major Driver In The Lung Cancer Drugs Market ­– Rise In The Prevalence Rate Of Lung Cancer
According to a World Health Organisation report, cancer killed approximately 10 million people in 2020, with lung cancer accounting for the greatest number of fatalities (1.80 million).

View More On The Lung Cancer Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Key Lung Cancer Drugs Market Segments
1) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)
2) By End User: Hospitals, Clinics, Other End-Users
3) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

Recent Lung Cancer Drugs Market Trend – Adopting Targeted Drug Therapy In Combination With Other Therapies
It entails the use of immunotherapy medications in conjunction with other therapies such as chemotherapy to aid in the early detection, prevention, and treatment of the disease. In this regard, pharmaceutical companies are developing targeted medication therapies for better lung cancer diagnosis and therapy. Merck and Co., for example, produced pembrolizumab, a medication that helps the immune system recognise and destroy cancer cells when used in conjunction with chemotherapy. Patients’ lung cancer status improved as a result of this combined therapy. Merck and Co. manufactures and sells the medicine under the brand name Keytruda.

Lung Cancer Drugs Market Prominent Players
Major players in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKlin, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation.

Request A Sample Of The Global Lung Cancer Drugs Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2567&type=smp

The Lung Cancer Drugs Global Market Report 2023  provides a comprehensive overview on the lung cancer drugs market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Lung cancer drugs are anti-angiogenic medications used to treat lung cancer. Lung cancer is a kind of cancer that reduces the lungs’ ability to provide oxygen to the bloodstream due to uncontrolled growth of lung tissues. Lung cancer treatment options include surgery, chemotherapy, radiation therapy, and targeted therapy. Lung cancer is classified into two types based on the size of the tumour cells: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

View More Related Reports –
Cancer Biologics Global Market Report 2023
Cancer Diagnostics Global Market Report 2023
Drugs For Hormonal Replacement Therapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model